Ophthalmology Times - Ophthalmology news, articles, and events
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Ophthalmologists: Castor oil shouldn’t be rubbed in the eyes, no …
Aug 8, 2023 · Ophthalmologists are issuing a warning not to use castor oil as a way to treat vision problems amid claims circulating on TikTok. In its heyday, castor oil was considered a jack-of-all-trades home remedy, used as a laxative, a moisturizer and …
Breaking down the dorzolamide shortage - Ophthalmology Times
Aug 9, 2019 · Editor’s Note: Welcome to “Let's Chat,” a blog series featuring contributions from members of the ophthalmic community.These blogs are an opportunity for ophthalmic bloggers to engage with readers with about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform.
Physicians sort out pros and cons of several new IOLs on the market
Nov 12, 2021 · Monofocal IOLs The monofocal category was expanded recently with 2 novel aspheric hydrophobic acrylic lenses—the TECNIS Eyhance (ICB00, Johnson + Johnson Vision) and the Clareon (Alcon). The Eyhance IOL has extended depth of focus (EDoF)-like qualities through the design of the central 1 mm of its optic. However, the Eyhance was not approved as an EDoF lens and surgeons cannot charge a ...
Nicox publishes results of Phase 3 trial of NCX 470 for treatment …
Mar 20, 2024 · Nicox SA announced results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.. According to the company, NCX 470 is a novel NO-donating bimatoprost eye drop currently in Phase 3 ...
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
Oct 14, 2024 · Key Takeaways. enVista Envy IOLs provide a continuous range of vision with high dysphotopsia tolerance, enhancing cataract surgery outcomes. U.S. and Canadian trials showed high patient satisfaction, with minimal issues related to glare and close object viewing.
Intense pulsed light for treatment of dry eye disease
Oct 31, 2024 · Joanne F. Shen, MD, director of the dry eye clinic at Mayo Clinic's campus in Phoenix, Arizona, and a research team studied 35 patients treated with IPL/MGX. The team reviewed demographics, ocular histories, Standard Patient Evaluation of Eye Dryness 2 symptom survey scores, slit-lamp examinations and meibomian gland evaluations at baseline and at each visit before IPL/MGX treatments.
Statin use may cause certain eye disorders, according to study
Dec 9, 2008 · Portland, OR-Eye disorders related to statin use were reported in the Jupiter Study led by F.W. Fraunfelder, MD, Casey Eye Institute, Oregon Health & Sciences University.The medication used to lower patients’ cholesterol levels, thus helping prevent coronary heart disease, stroke, and other deaths related to high cholesterol levels, is related to certain eye disorders in about 0.1% of patients.
Deciding Between Multifocals and Light Adjustable Lenses
Oct 10, 2023 · Sharon Richens, MD, FACS: Part of the conversation was how do you integrate both multifocals and light adjustable [lenses] into the practice. What is the role for the different people in the practice? And after you begin to introduce the idea to the patient, how do you follow through on that?
Johnson & Johnson launches TECNIS Odyssey IOL in US
Oct 1, 2024 · Johnson & Johnson is expanding the launch of its presbyopia-correcting intraocular lense (IOL), TECNIS Odyssey, in the US.. The TECNIS Odyssey IOL is a new full vision range IOL, built on the TECNIS platform from Johnson & Johnson, which according to the company provides two times better contrast in low lighting than PanOptix. 1 Peter Menziuso, company group chairman, Vision, Johnson & Johnson ...